Wenger Vieli advises Xeltis on securing EUR 15M in its Series D2 Financing Round
Wenger Vieli has acted as legal advisor to Xeltis, a clinical-stage company developing medical devices enabling cardiovascular restoration, on securing EUR 15 million in equity and license fees from the lead investor as cornerstone funding in its ongoing Series D2 financing round.
The round is led by Grand Pharmaceutical Group, a global comprehensive pharmaceutical enterprise based in the People’s Republic of China.
Xeltis is a Swiss/Dutch clinical-stage medical device company with registered seat in Eindhoven offering the most advanced polymer-based restorative devices for cardiovascular treatment.
The team was led by Beat Speck (partner, venture capital / m&a, pictured) and included Dominik Rietiker (associate, venture capital / m&a) and Andrea Christen (associate, notarial services).
